The American Society of Human Genetics (ASHG), in collaboration with key advocacy partners, continues to champion a vital message on Capitol Hill: robust and sustained funding for the National Institutes of Health (NIH) is not merely a budgetary line item—it is the bedrock of scientific progress and the primary source of hope for millions of Americans living with rare, often debilitating, genetic conditions.
At the heart of this advocacy lies the Undiagnosed Diseases Network (UDN), a nationwide research initiative that serves as a beacon of progress. By bridging the gap between clinical care and fundamental genomic research, the UDN has become a powerful case study for the tangible impact of federal research investment. To better understand this impact, ASHG recently engaged with a patient participant whose four-decade journey through the medical wilderness highlights the transformative power of modern genomics.
The Diagnostic Odyssey: A Chronology of Discovery
For many patients with rare diseases, the "diagnostic odyssey"—the time between the onset of symptoms and receiving a definitive diagnosis—can last decades. The participant interviewed for this report, who requested anonymity, provides a harrowing look at what happens when medical science lacks the tools to see what is hidden in the human genome.
The Early Years: A Dark Spiral
The participant’s journey began at just 18 months old. While their peers were reaching developmental milestones, this child was exhibiting limb abnormalities that baffled pediatric specialists. The ensuing 13 years were marked by what the participant describes as a "dark spiral" of painful, invasive testing and surgical procedures. In an era before the widespread adoption of next-generation sequencing, these interventions were often futile.
"Medical treatments and tests of the time were something akin to cruel, especially as a child," the participant recalls. By their teenage years, frustrated by the lack of answers and the physical toll of the diagnostic process, the participant made a difficult choice: they stopped seeking a diagnosis. With doctors warning they might not survive past their twenties, the participant shifted their focus toward living a meaningful life within the constraints of their mystery illness.
The Turning Point: Accessing the UDN
The landscape of medical science shifted dramatically over the next three decades. In 2020, at the age of 42, the participant sought a consultation with neurologists and geneticists at the University of Washington. These specialists recognized that the participant’s case required the highly specialized, collaborative approach offered by the UDN.
The UDN, a clinical and research network funded by the NIH, is designed for exactly these "unsolvable" cases. By pooling the expertise of clinicians and basic scientists across the country, the UDN utilizes advanced diagnostic tools—including whole-genome sequencing and functional studies—to uncover disease mechanisms that remain invisible to conventional clinical diagnostics.
The Breakthrough: Finding the "Intronic" Needle in a Haystack
After 43 years of uncertainty, the UDN team achieved what had been impossible for the previous four decades. Through advanced genetic testing, the team identified a known genetic variant for Charcot-Marie-Tooth disease type 2A (CMT2A).
Critically, the diagnosis was found on a region of the DNA known as introns—non-coding sequences that are often ignored or entirely bypassed during standardized, commercial genetic testing. This breakthrough highlights the necessity of the UDN’s commitment to deep-dive genomic research; it is not enough to test the "standard" markers. True diagnostic success often requires looking where others have previously stopped.
The Ripple Effect of Diagnosis
The impact of this discovery extended far beyond the participant. For their family, the diagnosis provided long-sought closure. It also provided immediate, life-altering medical information: the participant was able to inform their siblings that they were not carriers of the condition, effectively ending a generation of anxiety.
Furthermore, the diagnosis granted the participant entry into a community. "It meant finally understanding the complicated, rare body that I had inhabited for so long," the participant explained. With access to peer support and condition-specific knowledge, the participant saw a marked improvement in their daily health and comfort within weeks—a testament to the power of community and informed self-care.
Implications for Future Therapies
The UDN’s work did not stop at identifying the cause; it moved toward potential intervention. Because the network functions as a research entity, they were able to offer the participant a custom antisense oligonucleotide (ASO) therapy tailored to their unique genetic profile.
While the participant ultimately opted against the therapy due to the advanced stage of their disability and the inherent risks of such a treatment, the offer itself represents the cutting edge of precision medicine. "I feel so much gratitude for the medical research community," the participant noted. "I know that people earlier in their disability progression will soon have access to much more effective and humane treatments because of this work."
The Role of Advocacy in Genomic Research
The UDN is more than a clinical service; it is a vital component of the broader ASHG mission to ensure that human genetics and genomics remain a federal priority. As ASHG advocates for NIH funding, stories like this are essential tools for communicating the potential of the field to policymakers.
A New Role: The Patient as Advocate
Having spent a lifetime navigating the medical system, the participant now views their role as an advocate for the next generation of patients. Drawing on their history of peer support within the disability community, they now seek to bridge the gap between patients and researchers.
"It is my responsibility to help people still searching to find their own path forward," the participant said. "It is also equally important to work with the medical research community to connect with those on the front lines of knowledge, in ways that meaningfully drive us forward for the benefit of everyone."
The Researcher’s Mandate: Understanding the Human Element
The participant’s message to the scientific community is a poignant reminder of the stakes involved in rare disease research:
- Isolation: Living with a rare, congenital disease is an inherently isolating experience. Research provides the "key" to unlocking not just a medical answer, but a sense of identity and belonging.
- Access: For many, a diagnosis is the only gateway to support systems, community resources, and specialized care.
- The Human Cost: Researchers must recognize that their work is not just about sequences and data; it is about guiding the lives of families who have often spent years in a state of diagnostic limbo.
Conclusion: Sustaining the Momentum
The success of the UDN, as evidenced by this participant’s journey, underscores the necessity of continued, robust funding for the NIH. The ability to decode the human genome and translate those findings into clinical practice is a triumph of modern science, but it is also a resource-intensive endeavor.
As ASHG continues its advocacy efforts, the organization emphasizes that the infrastructure provided by the UDN—clinical expertise, genomic data integration, and a dedication to the "unsolvable"—is an essential investment in the nation’s health. By supporting these networks, Congress and the American public are not just funding research; they are providing hope, community, and answers to those who have waited a lifetime for them.
The American Society of Human Genetics (ASHG) extends its profound gratitude to the patient participant for sharing their story. Special thanks to the clinical and research team, including Azma Parhin, MD, Research Coordinator, and Andrew Stergachis, MD, PhD, for their efforts in facilitating this insight into the life-changing work of the Undiagnosed Diseases Network.
For more information on how to support these efforts or to access resources regarding the current landscape of genomic advocacy, please visit the ASHG Advocacy Center.
About the Author
